UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...
Release Date: March 10, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
UroGen Pharma Ltd (NASDAQ:URGN) submitted a new drug application for UGN 102 ahead of schedule, with FDA review underway and a target date set for June 13th.
The Envision phase 3 trial for UGN 102 demonstrated a compelling complete response rate of 79.6% at 3 months and an 82.3% duration of response at 12 months.
UroGen Pharma Ltd (NASDAQ:URGN) reported a strong balance sheet with $241.7 million in cash equivalents and marketable securities, positioning them well for future growth.
The company achieved a 12% year-over-year increase in sales for their commercial product, Jelmyto, indicating strong market demand.
UroGen Pharma Ltd (NASDAQ:URGN) is expanding its sales force from 52 to 83 representatives in anticipation of the UGN 102 launch, demonstrating a commitment to commercial preparedness.
UroGen Pharma Ltd (NASDAQ:URGN) reported a net loss of $126.9 million for the full year 2024, an increase from the $102.2 million loss in 2023.
Research and development expenses increased significantly to $57.1 million in 2024 from $45.6 million in 2023, driven by manufacturing and regulatory expenses.
SG&A expenses rose to $121.2 million in 2024 from $93.3 million in 2023, primarily due to commercial preparation activities for UGN 102.
The company anticipates using a miscellaneous J code for UGN 102 initially, which may complicate reimbursement processes for providers.
UroGen Pharma Ltd (NASDAQ:URGN) faces potential challenges in market access and reimbursement during the initial launch period of UGN 102 due to the generic J code.
Warning! GuruFocus has detected 4 Warning Signs with URGN.
Q: You noted on the call that you anticipate approval in the recurrent setting. Do you anticipate that UGN 102 could still be used in the about 10% of patients or so that are ineligible for surgery, which would be the frontline setting, and would this then require it to be used off label? A: Liz Barrett, CEO: Yes, that would be considered off-label, so we wouldn't be able to promote there. It would be up to the physician to work with their insurance company to ensure payment. This doesn't change our revenue projections, as we still believe UGN 102 will generate over a billion dollars in revenue. Physicians have expressed a desire to make this choice, and we are considering whether to conduct clinical work in this space.
Q: On UGN 102, as you think about the potential FDA approval later this summer, how should investors think about the initial launch trajectory, perhaps relative to Gelido or other potential benchmarks? A: David Lynn, Chief Commercial Officer: We intend to continue educating our physician provider universe and maintaining support. The overall shape of the launch curve is modeled similarly to Gelido, although the absolute numbers will be larger due to the patient population. We are considering pricing in the $18,000 to $19,000 per dose range.
Q: With respect to UGN 102 and the projected reimbursement environment, can you provide additional granularity regarding the difference in reimbursement level and market access during the period immediately after launch with a generic J code versus a specific J code? A: David Lynn, Chief Commercial Officer: Initially, we anticipate using a miscellaneous J code, which may result in a longer reimbursement process of about 50 to 60 days. This will improve with a permanent J code expected by January 2026. We will support accounts through this period, similar to our approach with Jamio.
Q: Regarding the pipeline development activities, can you give us an update on how enrollment kinetics appear to be progressing in the UGN 103 program and if you still expect to report data from that trial either next year or in 2027? A: Mark Schoenberg, Chief Medical Officer: We anticipate completing enrollment for the Utopia trial this year, with data expected in 2026 and potential approval in 2027. The trial is progressing well, and we are optimistic about maintaining this timeline.
Q: Given the impressive durability that the Envision data has shown, have you stress-tested potentially higher pricing for UGN 102, and what are your payer reactions? A: Liz Barrett, CEO: We are revisiting our pricing strategy due to the impressive durability data. We believe there is an opportunity to increase pricing slightly and are conducting research to refine our assumptions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
38 minutes ago
- Business Insider
‘Keep an Eye on the Bigger Picture,' Says Morgan Stanley About Tesla Stock
Tesla (NASDAQ:TSLA) stock took a sharp hit last week after Elon Musk and Donald Trump – once close buddies – turned on each other in a public social media spat that quickly became an online spectacle. While the internet grabbed its popcorn to watch the drama/comedy unfold, investors were less amused, driving the stock down and wiping out a record $152 billion in market value. Confident Investing Starts Here: Trump warned he might yank Elon's federal subsidies and contracts, while Musk took jabs at Trump's links to Jeffrey Epstein and called for his impeachment. Now, Trump says he's considering ditching his Tesla. But what does Wall Street have to say about all this madness? Morgan Stanley analyst Adam Jonas, one of the Street's biggest TSLA bulls, shared a 'few 'pith and marrow' thoughts' in the wake of the public spat. According to Trump, the whole thing kicked off because Musk was upset his 'Big Beautiful Bill' was not beneficial to Tesla. However, Jonas makes short shrift of the implications. 'We do not believe the phasing out of EV tax credits from the BBB (Big Beautiful Bill) is material to the long term outlook for TSLA,' the analyst said While Musk's involvement with the Trump administration and his increasingly polarizing politics were the cue from a massive drop in sales for Tesla earlier this year, Jonas does not think the argument will help bring back buyers that once considered buying a Tesla but were turned off by Musk's recent activities. In fact, Jonas thinks the argument could 'potentially (temporarily) alienate multiple sides of the political spectrum.' Yet, zooming out, Jonas thinks it's important to keep an eye on the bigger picture and that offers plenty of promise. 'While emotions are running high, we are not convinced the longer-term vectors that drive the stock's value have changed here,' he said. ' AI leadership, autonomy/robotics, manufacturing, supply chain re-architecture, renewable power, critical infrastructure… Tesla still holds so many valuable cards that are largely apolitical, in our opinion.' Nevertheless, investors should prepare for a rocky ride over the near-term. Donning his 'trading cap,' Jonas feels more confident about short-term volatility than about the stock's immediate direction. The analyst says he's sticking with his $410 price target on Tesla shares, even as he braces for the stock to post further losses. That figure implies a one-year gain of 36%. Meanwhile, Jonas maintains an Overweight rating (i.e., Buy). (To watch Jonas' track record, click here) That view, however, stands in contrast to the broader Street sentiment. Based on a mix of 16 Buys, 10 Holds, and 10 Sells, the analyst consensus rates the stock a Hold (i.e., Neutral). Going by the $285.91 average target, the shares are expected stay range-bound for the foreseeable future. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.


Business Insider
an hour ago
- Business Insider
Lululemon Athletica (LULU) Gets a Hold from Barclays
Barclays analyst Adrienne Yih maintained a Hold rating on Lululemon Athletica (LULU – Research Report) on June 6 and set a price target of $270.00. The company's shares closed last Friday at $265.27. Confident Investing Starts Here: Yih covers the Consumer Cyclical sector, focusing on stocks such as American Eagle, Dick's Sporting Goods, and VF. According to TipRanks, Yih has an average return of 6.4% and a 49.70% success rate on recommended stocks. In addition to Barclays, Lululemon Athletica also received a Hold from Morgan Stanley's Alexandra Straton in a report issued yesterday. However, on June 6, KeyBanc reiterated a Buy rating on Lululemon Athletica (NASDAQ: LULU). Based on Lululemon Athletica's latest earnings release for the quarter ending February 2, the company reported a quarterly revenue of $3.61 billion and a net profit of $748.4 million. In comparison, last year the company earned a revenue of $3.21 billion and had a net profit of $669.47 million


Business Upturn
an hour ago
- Business Upturn
Ericsson bags multi-year NOC Managed Services contract with Bharti Airtel
Ericsson (NASDAQ: ERIC) has been awarded a significant multi-year Network Operations Center (NOC) Managed Services contract by Bharti Airtel, reinforcing the strong and enduring partnership between the two telecom giants. This strategic collaboration highlights Ericsson's leadership in managed services and its commitment to delivering superior network performance and value to Airtel's customers. Under this new agreement, Ericsson will deploy its advanced intent-based operations through a centralized NOC to efficiently manage Bharti Airtel's diverse network services. These include 4G, 5G Non-Standalone (NSA), 5G Standalone (SA), Fixed Wireless Access (FWA), Private Networks, and Network Slicing. The move aims to enhance network reliability, scalability, and innovation across Airtel's pan-India footprint. Ericsson's state-of-the-art NOC will play a crucial role in managing and scaling Airtel's expansive network infrastructure, especially focusing on expanding Fixed Wireless Access and Network Slicing capabilities throughout the country. This will empower Airtel to offer improved connectivity solutions and cater to evolving customer demands in the 5G era. Randeep Sekhon, CTO of Bharti Airtel, stated, 'We are excited to enhance our strong collaboration with Ericsson as we pursue our goal of creating a future-ready network that delivers an exceptional experience for our customers. We believe that these innovative technologies will empower us to meet the growing data demands of consumers in a digitally connected India.' With a partnership spanning over 25 years, Ericsson and Bharti Airtel have collaborated across multiple generations of mobile communication technologies. This latest contract follows Airtel's recent collaboration with Ericsson on 5G Core technology, further driving the evolution of India's 5G ecosystem. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at